{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T18:21:09Z","timestamp":1791224469701,"version":"4.1.0"},"reference-count":31,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"10","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO"],"published-print":{"date-parts":[[2017,4,1]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p> This phase I expansion cohort study evaluated the safety and clinical activity of mirvetuximab soravtansine (IMGN853), an antibody\u2013drug conjugate consisting of a humanized anti\u2013folate receptor alpha (FR\u03b1) monoclonal antibody linked to the tubulin-disrupting maytansinoid DM4, in a population of patients with FR\u03b1-positive and platinum-resistant ovarian cancer. <\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p> Patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer received IMGN853 at 6.0 mg\/kg (adjusted ideal body weight) once every 3 weeks. Eligibility included a minimum requirement of FR\u03b1 positivity by immunohistochemistry (\u2265 25% of tumor cells with at least 2+ staining intensity). Adverse events, tumor response (via Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1), and progression-free survival (PFS) were determined. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p> Forty-six patients were enrolled. Adverse events were generally mild (\u2264 grade 2), with diarrhea (44%), blurred vision (41%), nausea (37%), and fatigue (30%) being the most commonly observed treatment-related toxicities. Grade 3 fatigue and hypotension were reported in two patients each (4%). For all evaluable patients, the confirmed objective response rate was 26%, including one complete and 11 partial responses, and the median PFS was 4.8 months. The median duration of response was 19.1 weeks. Notably, in the subset of patients who had received three or fewer prior lines of therapy (n = 23), an objective response rate of 39%, PFS of 6.7 months, and duration of response of 19.6 weeks were observed. <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p> IMGN853 exhibited a manageable safety profile and was active in platinum-resistant ovarian cancer, with the strongest signals of efficacy observed in less heavily pretreated individuals. On the basis of these findings, the dose, schedule, and target population were identified for a phase III trial of IMGN853 monotherapy in patients with platinum-resistant disease. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.2016.69.9538","type":"journal-article","created":{"date-parts":[[2017,2,23]],"date-time":"2017-02-23T17:11:27Z","timestamp":1487869887000},"page":"1112-1118","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":210,"title":["Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha\u2013Targeting Antibody\u2013Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study"],"prefix":"10.1200","volume":"35","author":[{"given":"Kathleen N.","family":"Moore","sequence":"first","affiliation":[{"name":"Kathleen N. Moore, University of Oklahoma Health Sciences Center, Oklahoma City, OK; Lainie P. Martin, Fox Chase Cancer Center, Philadelphia, PA; David M. O\u2019Malley, Ohio State University James Cancer Center, Columbus, OH; Ursula A. Matulonis, Dana-Farber Cancer Institute; Michael J. Birrer, Massachusetts General Hospital, Boston; Rodrigo Ruiz-Soto, ImmunoGen, Waltham, MA; Jason A. Konner, Memorial Sloan Kettering Cancer Center, New York, NY; Raymond P. Perez, University of Kansas, Fairway, KS; and Todd M..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lainie P.","family":"Martin","sequence":"additional","affiliation":[{"name":"Kathleen N. Moore, University of Oklahoma Health Sciences Center, Oklahoma City, OK; Lainie P. Martin, Fox Chase Cancer Center, Philadelphia, PA; David M. O\u2019Malley, Ohio State University James Cancer Center, Columbus, OH; Ursula A. Matulonis, Dana-Farber Cancer Institute; Michael J. Birrer, Massachusetts General Hospital, Boston; Rodrigo Ruiz-Soto, ImmunoGen, Waltham, MA; Jason A. Konner, Memorial Sloan Kettering Cancer Center, New York, NY; Raymond P. Perez, University of Kansas, Fairway, KS; and Todd M..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"O\u2019Malley","sequence":"additional","affiliation":[{"name":"Kathleen N. Moore, University of Oklahoma Health Sciences Center, Oklahoma City, OK; Lainie P. Martin, Fox Chase Cancer Center, Philadelphia, PA; David M. O\u2019Malley, Ohio State University James Cancer Center, Columbus, OH; Ursula A. Matulonis, Dana-Farber Cancer Institute; Michael J. Birrer, Massachusetts General Hospital, Boston; Rodrigo Ruiz-Soto, ImmunoGen, Waltham, MA; Jason A. Konner, Memorial Sloan Kettering Cancer Center, New York, NY; Raymond P. Perez, University of Kansas, Fairway, KS; and Todd M..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula A.","family":"Matulonis","sequence":"additional","affiliation":[{"name":"Kathleen N. Moore, University of Oklahoma Health Sciences Center, Oklahoma City, OK; Lainie P. Martin, Fox Chase Cancer Center, Philadelphia, PA; David M. O\u2019Malley, Ohio State University James Cancer Center, Columbus, OH; Ursula A. Matulonis, Dana-Farber Cancer Institute; Michael J. Birrer, Massachusetts General Hospital, Boston; Rodrigo Ruiz-Soto, ImmunoGen, Waltham, MA; Jason A. Konner, Memorial Sloan Kettering Cancer Center, New York, NY; Raymond P. Perez, University of Kansas, Fairway, KS; and Todd M..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason A.","family":"Konner","sequence":"additional","affiliation":[{"name":"Kathleen N. Moore, University of Oklahoma Health Sciences Center, Oklahoma City, OK; Lainie P. Martin, Fox Chase Cancer Center, Philadelphia, PA; David M. O\u2019Malley, Ohio State University James Cancer Center, Columbus, OH; Ursula A. Matulonis, Dana-Farber Cancer Institute; Michael J. Birrer, Massachusetts General Hospital, Boston; Rodrigo Ruiz-Soto, ImmunoGen, Waltham, MA; Jason A. Konner, Memorial Sloan Kettering Cancer Center, New York, NY; Raymond P. Perez, University of Kansas, Fairway, KS; and Todd M..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond P.","family":"Perez","sequence":"additional","affiliation":[{"name":"Kathleen N. Moore, University of Oklahoma Health Sciences Center, Oklahoma City, OK; Lainie P. Martin, Fox Chase Cancer Center, Philadelphia, PA; David M. O\u2019Malley, Ohio State University James Cancer Center, Columbus, OH; Ursula A. Matulonis, Dana-Farber Cancer Institute; Michael J. Birrer, Massachusetts General Hospital, Boston; Rodrigo Ruiz-Soto, ImmunoGen, Waltham, MA; Jason A. Konner, Memorial Sloan Kettering Cancer Center, New York, NY; Raymond P. Perez, University of Kansas, Fairway, KS; and Todd M..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd M.","family":"Bauer","sequence":"additional","affiliation":[{"name":"Kathleen N. Moore, University of Oklahoma Health Sciences Center, Oklahoma City, OK; Lainie P. Martin, Fox Chase Cancer Center, Philadelphia, PA; David M. O\u2019Malley, Ohio State University James Cancer Center, Columbus, OH; Ursula A. Matulonis, Dana-Farber Cancer Institute; Michael J. Birrer, Massachusetts General Hospital, Boston; Rodrigo Ruiz-Soto, ImmunoGen, Waltham, MA; Jason A. Konner, Memorial Sloan Kettering Cancer Center, New York, NY; Raymond P. Perez, University of Kansas, Fairway, KS; and Todd M..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Ruiz-Soto","sequence":"additional","affiliation":[{"name":"Kathleen N. Moore, University of Oklahoma Health Sciences Center, Oklahoma City, OK; Lainie P. Martin, Fox Chase Cancer Center, Philadelphia, PA; David M. O\u2019Malley, Ohio State University James Cancer Center, Columbus, OH; Ursula A. Matulonis, Dana-Farber Cancer Institute; Michael J. Birrer, Massachusetts General Hospital, Boston; Rodrigo Ruiz-Soto, ImmunoGen, Waltham, MA; Jason A. Konner, Memorial Sloan Kettering Cancer Center, New York, NY; Raymond P. Perez, University of Kansas, Fairway, KS; and Todd M..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Birrer","sequence":"additional","affiliation":[{"name":"Kathleen N. Moore, University of Oklahoma Health Sciences Center, Oklahoma City, OK; Lainie P. Martin, Fox Chase Cancer Center, Philadelphia, PA; David M. O\u2019Malley, Ohio State University James Cancer Center, Columbus, OH; Ursula A. Matulonis, Dana-Farber Cancer Institute; Michael J. Birrer, Massachusetts General Hospital, Boston; Rodrigo Ruiz-Soto, ImmunoGen, Waltham, MA; Jason A. Konner, Memorial Sloan Kettering Cancer Center, New York, NY; Raymond P. Perez, University of Kansas, Fairway, KS; and Todd M..."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2014.02.038"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.4-2-87"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.3.389"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/0090-8258(90)90174-J"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.4.1494"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2004.01.001"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-007-9048-0"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv250"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2007.11.020"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19980417)79:2<121::AID-IJC4>3.0.CO;2-V"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S40947"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-014-9539-8"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2014.10.002"},{"key":"B15","first-page":"118","volume":"4","author":"Lutz RJ","year":"2015","journal-title":"Transl Cancer Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12044"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1021\/bc900315y"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.5b00175"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-3973"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-14-1095"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2016.05.020"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.msec.2014.06.002"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.14.3312"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.6606"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.51.4489"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2015.0064"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1021\/ar700108g"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/anie.201307628"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30030-4"},{"key":"B34","first-page":"225","volume":"5","author":"Raufi A","year":"2013","journal-title":"Cancer Manag Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-9-199"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2016.69.9538","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T09:02:21Z","timestamp":1653814941000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2016.69.9538"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,1]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,4,1]]}},"alternative-id":["10.1200\/JCO.2016.69.9538"],"URL":"https:\/\/doi.org\/10.1200\/jco.2016.69.9538","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,1]]},"assertion":[{"value":"2016-12-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}